Therapeutic efficacy of IL-17A antibody injection in preventing the development of colitis associated carcinogenesis in mice

Qi, Haili; Yang, Hang; Xu, Gang; Ren, Jingli; Wei, Hua; Shi, Yingpeng; Torsvik, Malvin; Florholmen, Jon; Cui, Guanglin

doi:10.1016/j.imbio.2014.09.002

Cited by 32 publications

(21 citation statements)

References 56 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Secukinumab, a human anti‐IL‐17A monoclonal antibody, was already tested in phase 3 trial in patients with psoriatic arthritis . Recently, in mouse models, the blockade by anti‐IL‐17A antibody therapy was used to suppress the development of colitis associated cancer or to reduce breast cancer–associated metastases . Thus, it would be relevant to test anti‐IL‐17A antibody such a treatment in animal model for chronic liver fibrosis and in model of HCC.…”

Section: Discussionmentioning

confidence: 99%

Progression of fibrosis in patients with chronic viral hepatitis is associated with IL‐17⁺ neutrophils

Jilkova

Afzal

Marche

et al. 2016

Liver International

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Progression of fibrosis in patients with chronic viral hepatitis is associated with IL‐17⁺ neutrophils

Jilkova

Afzal

Marche

et al. 2016

Liver International

View full text Add to dashboard Cite

show abstract

“…, those using tumor-infiltrating lymphocytes (TIL) and chimeric antigen receptors (CAR), are promising [87]. Similarly, antibodies have been engineered to block the action of the Th17 cell subset, which secretes interleukin 17, with consistent results in mice where antibody injection was followed by a decrease in the number of tumors [88]. In this paper, we suggest that personal history of infection/medication, including childhood diseases, could modify how the immune system responds to immunotherapy possibly altering its efficiency.…”

Section: Resultsmentioning

confidence: 99%

Infections and cancer: the “fifty shades of immunity” hypothesis

et al. 2017

View full text Add to dashboard Cite

BackgroundSince the beginning of the twentieth century, infection has emerged as a fundamental aspect of cancer causation with a growing number of pathogens recognized as oncogenic. Meanwhile, oncolytic viruses have also attracted considerable interest as possible agents of tumor destruction.DiscussionLost in the dichotomy between oncogenic and oncolytic agents, the indirect influence of infectious organisms on carcinogenesis has been largely unexplored. We describe the various ways – from functional aspects to evolutionary considerations such as modernity mismatches – by which infectious organisms could interfere with oncogenic processes through immunity. Finally, we discuss how acknowledging these interactions might impact public health approaches and suggest new guidelines for therapeutic and preventive strategies both at individual and population levels.SummaryInfectious organisms, that are not oncogenic neither oncolytic, may play a significant role in carcinogenesis, suggesting the need to increase our knowledge about immune interactions between infections and cancer.Electronic supplementary materialThe online version of this article (doi:10.1186/s12885-017-3234-4) contains supplementary material, which is available to authorized users.

show abstract

“…For instance, the release of cytokines from the tumor microenvironment may participate in the modulation of the proliferative activity of the stromal cell [ 37 ]. In our previous studies, we have demonstrated an elevated expression pattern of IL-17A in the tumor microenvironment of adenoma/CRC [ 25 , 38 , 39 ]. It has been found that IL-17A stimulates stem-like cells and promote the development of various types of cancers [ 40 – 43 ].…”

Section: Discussionmentioning

confidence: 99%

Temporal and spatial changes of cells positive for stem-like markers in different compartments and stages of human colorectal adenoma-carcinoma sequence

Cui

Zhu

et al. 2017

Oncotarget

Self Cite

View full text Add to dashboard Cite

Considerable evidence supports the idea that stem-like cells may play an essential role during the development of colorectal cancer (CRC). To accomplish this aim, we use immunohistochemistry (IHC) and double IHC with different potential stem-like markers, anti-musashi (Msi), anti-CD133, anti- LGR5 and anti-ALDH1 to examine the presentation of stem-like cells in different compartments including adenoma/CRC epithelium, transitional crypts and tumor stroma in colorectal adenoma and CRC. The results showed that cells positive for stem-like markers were remarkably increased in number and frequently observed in the adenoma/CRC epithelium, transitional crypts and tumor stroma. Notably, the population of cells positive for stem-liker markers was expanded from the base to the middle part of the transitional crypt in both adenoma and CRC tissues, reflecting that stem-like cells are likely involved in the process of colorectal tumorigenesis. Counting results showed that the grading scores of cells positive for LGR5 and ALDH1 in the adenoma/CRC epithelium were significantly increased relative with the control epithelium, and associated with the degree of dysplasia in the adenoma and node involvement in the CRC (all P < 0.05). In addition, the density of cells positive for stem–like markers in the adenomatous/cancerous stroma was also increased and paralleled an increase in the density of proliferative stromal cells labeled by PCNA, which were primarily identified as vimentin positive fibroblasts. Our results have revealed a changed temporal and spatial presentation of stem-like markers in different stages of human colorectal adenoma-carcinoma sequence, which might be a hallmark of the adenoma-carcinoma transition.

show abstract

Therapeutic efficacy of IL-17A antibody injection in preventing the development of colitis associated carcinogenesis in mice

Cited by 32 publications

References 56 publications

Progression of fibrosis in patients with chronic viral hepatitis is associated with IL‐17⁺ neutrophils

Progression of fibrosis in patients with chronic viral hepatitis is associated with IL‐17⁺ neutrophils

Infections and cancer: the “fifty shades of immunity” hypothesis

Temporal and spatial changes of cells positive for stem-like markers in different compartments and stages of human colorectal adenoma-carcinoma sequence

Contact Info

Product

Resources

About

Therapeutic efficacy of IL-17A antibody injection in preventing the development of colitis associated carcinogenesis in mice

Cited by 32 publications

References 56 publications

Progression of fibrosis in patients with chronic viral hepatitis is associated with IL‐17+ neutrophils

Progression of fibrosis in patients with chronic viral hepatitis is associated with IL‐17+ neutrophils

Infections and cancer: the “fifty shades of immunity” hypothesis

Temporal and spatial changes of cells positive for stem-like markers in different compartments and stages of human colorectal adenoma-carcinoma sequence

Contact Info

Product

Resources

About

Progression of fibrosis in patients with chronic viral hepatitis is associated with IL‐17⁺ neutrophils

Progression of fibrosis in patients with chronic viral hepatitis is associated with IL‐17⁺ neutrophils